{"name":"Ferrer Internacional S.A.","slug":"ferrer-internacional-s-a","ticker":"","exchange":"","domain":"","description":"Ferrer Internacional S.A. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments across various therapeutic areas. With a diverse portfolio of marketed drugs and a robust pipeline, Ferrer is committed to improving patient outcomes globally.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Furosemide-IR","genericName":"Furosemide-IR","slug":"furosemide-ir","indication":"Other","status":"marketed"},{"name":"Torasemide Prolonged Release","genericName":"Torasemide Prolonged Release","slug":"torasemide-prolonged-release","indication":"Other","status":"marketed"},{"name":"retapamulin 1% ointment","genericName":"retapamulin 1% ointment","slug":"retapamulin-1-ointment","indication":"Other","status":"marketed"},{"name":"torasemide-IR","genericName":"torasemide-IR","slug":"torasemide-ir","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"GF-001001-00","genericName":"GF-001001-00","slug":"gf-001001-00","indication":"Chronic hepatitis C","status":"phase_2"},{"name":"ozenoxacin 1% cream","genericName":"ozenoxacin 1% cream","slug":"ozenoxacin-1-cream","indication":"Treatment of impetigo caused by susceptible bacteria","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FNP-223","genericName":"FNP-223","slug":"fnp-223","indication":"Relapsing forms of multiple sclerosis","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"torasemide-PR","genericName":"torasemide-PR","slug":"torasemide-pr","indication":"Edema associated with congestive heart failure","status":"marketed"}]}],"pipeline":[{"name":"FNP-223","genericName":"FNP-223","slug":"fnp-223","phase":"phase_2","mechanism":"FNP-223 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"Furosemide-IR","genericName":"Furosemide-IR","slug":"furosemide-ir","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GF-001001-00","genericName":"GF-001001-00","slug":"gf-001001-00","phase":"phase_2","mechanism":"GF-001001-00 is a small molecule that targets the HCV NS5A protein.","indications":["Chronic hepatitis C","Hepatitis C virus infection"],"catalyst":""},{"name":"Torasemide Prolonged Release","genericName":"Torasemide Prolonged Release","slug":"torasemide-prolonged-release","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ozenoxacin 1% cream","genericName":"ozenoxacin 1% cream","slug":"ozenoxacin-1-cream","phase":"phase_3","mechanism":"Ozenoxacin is a quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.","indications":["Treatment of impetigo caused by susceptible bacteria"],"catalyst":""},{"name":"retapamulin 1% ointment","genericName":"retapamulin 1% ointment","slug":"retapamulin-1-ointment","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"torasemide-IR","genericName":"torasemide-IR","slug":"torasemide-ir","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"torasemide-PR","genericName":"torasemide-PR","slug":"torasemide-pr","phase":"marketed","mechanism":"Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.","indications":["Edema associated with congestive heart failure","Edema associated with hepatic cirrhosis","Edema associated with renal disease","Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFAzWXpaRHVxLVhYMktyaHducTgtS2k4aXl5STFaSHVxcVVVU2t1WXBGVVJkbE9KVXgyZlZZbGFHeFJUSmlnbFZBUzQtQjJyamQwaXZSWmJmNm1fRk0telNiOG82T1JiTElZZmg4?oc=5","date":"2025-12-31","type":"pipeline","source":"Market.us","summary":"Omega 3 Prescription Drugs Market Size, Share | CAGR of 7.8% - Market.us","headline":"Omega 3 Prescription Drugs Market Size, Share | CAGR of 7.8%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQdXFuXzZHVFBJTllsSWhHRzQ5aE5tdThyVHJUZFpaSUM1M0JtZ2hSXzFtQ1M0UXZyZ3IxWmFnalVoclZESWd5X25RVXpuLUpPMWRIOFdhUjNWa2x4V2lYWU42aDZpTUJQNnJPMWxiUW5XUER2dUJhZHhPZnBrZWM4QWtwelpuY254R0hMWUQzd3ZxX0pUM1lwOWFRNA?oc=5","date":"2025-11-10","type":"pipeline","source":"The Business Journals","summary":"Durham biotech bets on skin infection treatment with acquisition - The Business Journals","headline":"Durham biotech bets on skin infection treatment with acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNMGxNN01hdlZ6Y0tsZ3c1TTdldDdhc1RZd0daVGoxc2pCcEs5STFpY0FxWEh1SUVXdnhacXFwSmJlaHJyS2k0a1ctR2ZkNlBwQUs4R2JaRG5SMkNIRHZtYWhpMEJMamttZzNGWkJsc2l6SjF0SlhzQkczMkwtemJqbHA2c0RZbll1bnhOOGotUV9mRzU0U21oa0FKZXZlWl9UaHRGZ1d2ZXVMNm1yMXFaSmxZVy1qU2hOd0FOY204M0s0QTFrTlE4TEdyeENtSlJCOWM3alV5N0VGMkluNmx5Vmc4eTktN0pJSmxidmxzeWptdlNCdm94ZjExcl8wbTFFczhoRjNsMzJhVlV6amc?oc=5","date":"2025-02-20","type":"pipeline","source":"Business Wire","summary":"Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp - Business Wire","headline":"Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNeHlPN1hiclM5cFk4T0RncmwwOG5zSFVKMjZyZ1NzTVdWMVE3SU9LcWQwSHZpZklKSk5XTElJX1BOenFKc3U0X2tsanBMZERnSm9xblJ6eXRUYW44bXNjVHdZYVVZdkVjZUh0UFRxRmFGZjh6UlVRLVg1VGdOUzlab29KNTRsMWotX3EwYUp6NFlPR2xyVnJrcDYxUy1WUU0?oc=5","date":"2024-03-26","type":"pipeline","source":"European Biotechnology Magazine","summary":"Spanish Ferrer SA pays €122.5m for ALS candidate - European Biotechnology Magazine","headline":"Spanish Ferrer SA pays €122.5m for ALS candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQMmNvTXRSRTdEVzdTVDhsVnNFa0tZWWx2ODcxWDc5YWhKMnpYMjJnQzYyVDE4QUJwQ3AxajY2aWt2RUhnbG44TWlFNldudmdfVk8yc3NhN1hSQ0pTekJlZWRRV0diRkpvYWdXTmZyeXJTd3lNSmpxZy15b1NrNEszeFVpdW0wcjFqZ1JZMzhzRGhfcVVJSHZFajBiNVRFbm52RXROcUlReDhFTFJ1bG5ia2pNMkE3bHVuSzJtMG02UQ?oc=5","date":"2024-01-31","type":"trial","source":"Pharmaceutical Technology","summary":"Phase III study halted: Ferrer’s oral edaravone disappoints in ALS - Pharmaceutical Technology","headline":"Phase III study halted: Ferrer’s oral edaravone disappoints in ALS","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOT1ptSXNjbDdOQ3ljd1JVTHAzVmpNb0FRdExZWHotekxZZzMxbGl6MnpVX2NfM1RGdXJDd3cxYlBrQm02UXU5dmlHZnVHckRrU1ZFWXZrN2xaNm1IUzIwZXJXckpOMGM5YVpzSmFwaGU0bkRQeW1HMVRIamxmRWFQWQ?oc=5","date":"2023-02-22","type":"deal","source":"Pharmaceutical Technology","summary":"Ferrer signs licence deal with Asceneuron for ASN90 to treat PSP - Pharmaceutical Technology","headline":"Ferrer signs licence deal with Asceneuron for ASN90 to treat PSP","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-01-02","type":"deal","source":"ET HealthWorld","summary":"Hetero Labs Limited acquires Tarbis Farma in Spain - ET HealthWorld","headline":"Hetero Labs Limited acquires Tarbis Farma in Spain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNQlJGbXZFS184N3RYNHpLLWlIMUY1LTdQTEszTzFvVFlzdkRocVlNQnB5d01LcjFHS1Z2NlZaU3RRNXNiQVJKUWVld0lCTVFNRS1vaklmVEUtUENmQWFCWHlDbV9OUzVzY3ZlWFNHdjZYbkpFQU9UYmVDdS1QSUh4X0EzYm5pWnhobmlsSQ?oc=5","date":"2018-11-12","type":"pipeline","source":"grandviewresearch.com","summary":"Acute Repetitive Seizures Market Size | Industry Report, 2030 - grandviewresearch.com","headline":"Acute Repetitive Seizures Market Size | Industry Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNMDhJQW56MmN4YUVZenB4MmRmT1RWM205VThJcktnQlFzX2swNVNvSWYxeUE0RkphY0NkdkZtNHZPMUt6ekdMSDU4QmJwbWF3U3hiRXpkS3M5WkF1WEpyNV9CTlFyM3lpTER1OTdfZXhmdlJpLUJQUm5JR3d4Tl83TWpSMjk0bWxQRWZ2eHhLelRrQTJhUGYyOWRlZXJWdw?oc=5","date":"2016-06-21","type":"deal","source":"PR Newswire","summary":"Alexza Pharmaceuticals Acquired by Ferrer - PR Newswire","headline":"Alexza Pharmaceuticals Acquired by Ferrer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQS1ZqSzZuSDJoc2Q5ZjE0OW5NU2s2OUVuSUJSbzB5SHRndU92dDM2cFdGdFQyTUlqMnBTT1Vna01IY2d4WmoyYVJYWnp0TElESE1uMzRPNjYzTkQ2SEI3cEVWcWJ4YlBOMGlKRDd6ZVlMT2FJRDdhZ1VadlBJVU8xbEp6ME5sVmtLaTI3UDRibHRZNWZ6bkMtLVNMcnJ0SUpIQW9qWlBB?oc=5","date":"2016-05-10","type":"deal","source":"PR Newswire","summary":"Alexza Pharmaceuticals to be Acquired by Ferrer - PR Newswire","headline":"Alexza Pharmaceuticals to be Acquired by Ferrer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9hQmV5cFZJNzloT3BmUWZDOGZ5eGFmODZWVFFoYVpETHVpQXlMNWN1UHFuUndnZGtLbDhIYzdpeGZXZ1pBck5QTE5RQ0RFOW11cHhIdnJaSU9jTDRGU3A2RmNJMEpVTUxLMjlIU0M5VWJnMHlNM3E4cjVBZHc5UQ?oc=5","date":"2016-05-10","type":"deal","source":"BioSpace","summary":"Bay Area’s Alexza Pharma Sold in $35 Million Deal - BioSpace","headline":"Bay Area’s Alexza Pharma Sold in $35 Million Deal","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_2":2,"marketed":5,"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}